Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.70 |
| ▸ | ALB | P02768 | 2/20 | 0.70 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | GLI1 | P08151 | 1/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.70 |
| ▸ | NT5E | P21589 | 1/20 | 0.70 |
| ▸ | DPP4 | P27487 | 1/20 | 0.70 |
| ▸ | RORC | P51449 | 1/20 | 0.70 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.70 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.70 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.65 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.65 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.65 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.65 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12558298 | 1.00 | PTPN1 (0.70) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL16995362 | 1.00 | PTPN1 (0.70) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL19415219 | 1.00 | PTPN1 (0.70) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL12593102 | 1.00 | PTPN1 (0.70) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL15918172 | 0.94 | GPBAR1 (0.70) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL15917888 | 0.93 | GPBAR1 (0.62) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL16705023 | 0.92 | F3 (0.72) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL12134013 | 0.92 | F3 (0.72) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL16704695 | 0.92 | F3 (0.72) | PTPN1ALBGPBAR1USP2LMNA | |
| SCHEMBL16704682 | 0.92 | F3 (0.72) | PTPN1ALBGPBAR1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234042-B1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | POLA CHEM IND INC (JP) | 2025-08-13 | — | — | EP | disclosed |
| CN-113423470-B | Cosmetic compounding agent, cosmetic, and method for producing same | 三吉油脂株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-115192470-B | Oily composition | 宝丽化成工业有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117731675-A | Medical application of pentacyclic triterpene derivative, pentacyclic triterpene derivative and pharmaceutical composition containing pentacyclic triterpene derivative | 上海科技大学 | 2024-03-22 | — | — | CN | disclosed |
| EP-4234042-A1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | Pola Chemical Industries, Inc. (JP) | 2023-08-30 | — | — | EP | disclosed |
| CN-115192470-A | Oily composition | 宝丽化成工业有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-112694514-B | Pentacyclic triterpenoid TGR5 receptor agonist, and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-09-23 | — | — | CN | disclosed |
| EP-3925671-A1 | COSMETIC INGREDIENT, COSMETIC, AND PRODUCTION METHOD FOR COSMETIC | Miyoshi Oil & Fat Co., Ltd. (JP) | 2021-12-22 | — | — | EP | disclosed |
| US-20200368131-A1 | OIL-BASED COMPOSITION | POLA CHEM IND INC (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-3711746-A1 | OIL-BASED COMPOSITION | Pola Chemical Industries Inc. (JP) | 2020-09-23 | — | — | EP | disclosed |
| WO-2011153319-A1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20070072835-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072835-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072835-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-03-29 | — | — | US | disclosed |
| US-7091195-B2 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-08-15 | — | — | US | disclosed |
| US-20030186945-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2003-10-02 | — | — | US | disclosed |
| US-6569842-B2 | Method of preparing and use of prodrugs of betulinic acid derivatives | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2003-05-27 | — | — | US | disclosed |
| EP-1309605-A1 | PRODRUGS OF BETULINIC ACID DERIVATIVES FOR THE TREATMENT OF CANCER AND HIV | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020052352-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-02 | — | — | US | disclosed |
| WO-2002016395-A1 | PRODRUGS OF BETULINIC ACID DERIVATIVES FOR THE TREATMENT OF CANCER AND HIV | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072835-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | BET1, PGGT1B, RABGGTB | PTPN1 4209/4885ALB 3453/4885GPBAR1 99/4885 |
| US-20200368131-A1 | OIL-BASED COMPOSITION | CUTA, EBP, LIPA | PTPN1 3370/4885ALB 678/4885GPBAR1 2828/4885 |
| US-20030186945-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | BET1, PGGT1B, RABGGTB | PTPN1 4209/4885ALB 3453/4885GPBAR1 99/4885 |
| US-20020052352-A1 | Method of preparing and use of prodrugs of betulinic acid derivatives | BET1, PGGT1B, RABGGTB | PTPN1 4209/4885ALB 3453/4885GPBAR1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.